Biocardia Stock Today
| BCDA Stock | USD 1.18 0.07 5.60% |
PerformanceWeakest
| Odds Of DistressRisky
|
Biocardia is trading at 1.18 as of the 12th of February 2026, a 5.6 percent decrease since the beginning of the trading day. The stock's open price was 1.25. Biocardia has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 14th of November 2025 and ending today, the 12th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of March 2008 | Category Healthcare | Classification Health Care |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. The company has 10.61 M outstanding shares of which 216.07 K shares are currently shorted by private and institutional investors with about 3.26 trading days to cover. More on Biocardia
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biocardia Stock Highlights
| CEO | Peter Altman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBiocardia can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biocardia's financial leverage. It provides some insight into what part of Biocardia's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biocardia (BCDA) is traded on NASDAQ Exchange in USA and employs 17 people. Biocardia is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.27 M. Biocardia conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.61 M outstanding shares of which 216.07 K shares are currently shorted by private and institutional investors with about 3.26 trading days to cover.
Biocardia currently holds about 8.61 M in cash with (8.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49.
Check Biocardia Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Biocardia is $13.27 Million. Biocardia retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Biocardia Ownership Details
Biocardia Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Global Retirement Partners, Llc. | 2025-06-30 | 411 | |
| Jpmorgan Chase & Co | 2025-06-30 | 234 | |
| Advisor Group Holdings, Inc. | 2025-06-30 | 62.0 | |
| Sbi Securities Co Ltd | 2025-06-30 | 6.0 | |
| Tower Research Capital Llc | 2025-03-31 | 0.0 | |
| Cm Management, Llc | 2025-06-30 | 130 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 38.8 K | |
| Geode Capital Management, Llc | 2025-06-30 | 37.5 K | |
| Brown Advisory Holdings Inc | 2025-06-30 | 35.5 K | |
| Cetera Investment Advisers | 2025-06-30 | 20.3 K | |
| Commonwealth Equity Services Inc | 2025-06-30 | 18.1 K |
Biocardia Historical Income Statement
Biocardia Stock Against Markets
Biocardia Corporate Management
| Edward Gillis | Senior Devices | Profile | |
| Ian McNiece | Chief Officer | Profile | |
| Sujith Shetty | Chief Regulatory | Profile | |
| Sujith MBBS | Chief Regulatory | Profile | |
| Miranda Benvenuti | Investor Executive | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value - what Biocardia's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.